ReviewCurrent cardiology reports2018
Venous Thromboembolism and Cancer.
Review in Current cardiology reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 50 citations in OpenAlex.
- Frontier and hotspot evolution in pulmonary embolism: A bibliometric analysis from 2004 to 2023.Medicine · 2025Article
- Bone cement implantation syndrome in patients with cemented endoprostheses for metastatic bone disease in the femur.Journal of bone oncology · 2025Article
- Article
- The promise and limitations of artificial intelligence in CTPA-based pulmonary embolism detection.Frontiers in medicine · 2025Review
- The Impact of Cardiovascular Disease Gene Polymorphism and Interaction with Homocysteine on Deep Vein Thrombosis.ACS omega · 2024Article
- Artificial Intelligence Tool for Detection and Worklist Prioritization Reduces Time to Diagnosis of Incidental Pulmonary Embolism at CT.Radiology. Cardiothoracic imaging · 2023Article
- Review
- The Risk of Venous Thromboembolism after Thoracolumbar Spine Surgery: A Population-Based Cohort Study.Journal of clinical medicine · 2023Article
- Cancer-Associated Thrombosis: Epidemiology, Pathophysiological Mechanisms, Treatment, and Risk Assessment.Clinical Medicine Insights. Oncology · 2023Review
- Epidemiology and Treatment Patterns of Venous Thromboembolism: an Observational Study of Nationwide Time-Series Trends in Japan.Cardiology and therapy · 2022Article
- The ICU-venous thromboembolism score and tumor grade can predict inhospital venous thromboembolism occurrence in critical patients with tumors.World journal of surgical oncology · 2022Article
- A Review of the Past, Present and Future of Cancer-associated Thrombosis Management.Heart international · 2022Review
- Brazilian Position Statement on the Use Of Multimodality Imaging in Cardio-Oncology - 2021.Arquivos brasileiros de cardiologia · 2021Article
- Diagnostic performance of D-dimer in predicting venous thromboembolism and acute aortic dissection.European heart journal. Acute cardiovascular care · 2021Article
- Venous Thromboembolism in Hospitalized Melanoma Patients: Analysis from the National Inpatient Sample Database.International journal of general medicine · 2021Article
- Chemotherapy induced changes to fibrin clots properties in lung cancer: is it favorable?Journal of thoracic disease · 2019Article
- Anti-Thrombin, Anti-Adhesive, Anti-Migratory, and Anti-Proliferative Activities of Sulfated Galactans from the Tropical Green Seaweed,Marine drugs · 2018Article
- Solid Tumor Complicated With Venous Thromboembolism: A 10-Year Retrospective Cross-Sectional Study.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/HemostasisArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
purpose of reviewThis review aims to summarize the epidemiology, current pathophysiologic understanding, and state-of-the-art treatment of venous thromboembolism (VTE) in cancer patients. RECENT
findingsThe risk of VTE varies among cancer patients. Recently introduced prediction models better identify those at high risk of VTE. New mechanisms underlying hypercoagulability in cancer have been uncovered. Initial data on the efficacy of direct oral anticoagulants (DOACs) compared with low-molecular weight heparin to treat VTE in patients with cancer are promising. However, they may be associated with higher risk of gastrointestinal bleeding. VTE causes significant morbidity and mortality in cancer patients. Our understanding of the mechanisms of VTE, including those associated with cancer treatments, has significantly grown. The assessment of the benefit/risk balance of VTE treatment remains challenging in many patients with cancer. The introduction of DOACs has expanded treatment options, but knowledge on their efficacy and safety is incomplete.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.